Why the Pro-Gly-Pro Extension Matters in Semax Peptide Design

Why the Pro-Gly-Pro extension matters in Semax peptide design comes down to the difference between the short ACTH(4-7) fragment and the finished heptapeptide MEHFPGP. Adding Pro-Gly-Pro changes the C terminus, proteolytic susceptibility, conformational possibilities, metabolite profile, and overall experimental behavior of the molecule. The PGP segment was incorporated as a stabilizing design feature, but research also shows that PGP can have biological properties of its own, making the extension more than an inert protective tail.

The PGP extension is therefore a distinct structural question within Semax Research. Researchers need to distinguish the intact MEHFPGP peptide from ACTH(4-7), isolated PGP, Semax-derived metabolites, and other glyproline-containing peptides when interpreting degradation or biological-response experiments.

Research-use context for the Pro-Gly-Pro extension in Semax peptide design: InStrips materials are supplied for research and analytical investigation. Discussion of PGP-related stability, peptide metabolism, or experimental molecular responses is not intended to diagnose, treat, cure, or prevent any disease, injury, deficiency, absorption disorder, digestive condition, or other medical condition.

Semax Does Not End at ACTH(4-7)

The ACTH-derived portion of Semax contains four residues:

Met-Glu-His-Phe

If the molecule ended there, it would be ACTH(4-7).

Instead, Semax continues with:

Pro-Gly-Pro

to form:

Met-Glu-His-Phe-Pro-Gly-Pro

The Extension Creates Three New Peptide Bonds and Positions

Adding PGP creates Semax positions:

• Pro5
• Gly6
• Pro7

It also converts phenylalanine from the C-terminal residue of ACTH(4-7) into an internal residue followed by Pro5.

Changing the Terminus Changes the Molecule

A peptide's terminal residues influence how it interacts with proteolytic enzymes.

ACTH(4-7) presents phenylalanine at the C terminus.

Semax presents proline instead.

This alone can change susceptibility to carboxypeptidase-associated degradation.

The Phe-Pro Bond Is a Designed Structural Junction

The peptide bond joining Phe4 to Pro5 links the ACTH-derived and glyproline regions.

This bond is absent from native ACTH at the corresponding location.

Its presence can affect:

• local backbone orientation
• enzyme recognition
• conformational flexibility

Proline Has Unusual Backbone Chemistry

Proline differs from most standard amino acids because its side chain reconnects to the backbone nitrogen.

This cyclic structure constrains backbone movement.

Proline-containing sequences can therefore interact differently with proteases than otherwise similar peptides.

Semax Contains Two Prolines

They occupy positions 5 and 7.

The PGP region thus begins and ends with a conformationally restricted residue.

Glycine Creates the Opposite Structural Tendency

Between those two prolines sits glycine.

Glycine has only hydrogen as its side chain and permits a comparatively broad range of backbone conformations.

PGP therefore combines:

• restricted Pro
• flexible Gly
• restricted Pro

This Creates a Distinctive C-Terminal Motif

The sequence should not be understood simply as three extra residues that increase length.

PGP creates a particular backbone environment at the C terminus.

The PGP Extension Was Intended to Increase Stability

One rationale for Semax design was to make the ACTH-derived fragment less susceptible to rapid enzymatic degradation.

Short regulatory peptides can otherwise be cleaved rapidly by:

• aminopeptidases
• endopeptidases
• carboxypeptidases

Stability Is Relative, Not Absolute

The word stable can be misleading if interpreted as meaning that Semax does not undergo proteolysis.

Experimental research shows that Semax is degraded enzymatically.

The relevant question is how its degradation profile compares with related sequences.

Semax Proteolysis Can Begin at the N Terminus

Studies using aminopeptidase-containing systems have shown that N-terminal processing contributes importantly to Semax degradation.

Removing N-terminal residues can generate shorter Semax-related fragments.

Semax-5 Is One Reported Proteolytic Product

A commonly discussed fragment is:

His-Phe-Pro-Gly-Pro

This five-residue species demonstrates that PGP can remain attached to part of the ACTH-derived region after upstream cleavage.

Parent Peptide and Semax-5 Are Not the Same Molecule

The loss of Met-Glu changes:

• sequence length
• molecular mass
• charge
• N-terminal chemistry

A biological assay should distinguish the intact parent peptide from metabolites where possible.

The PGP Motif Can Persist During Proteolysis

Pro-Gly-Pro itself is comparatively resistant to several proteolytic systems investigated experimentally.

This relative persistence helps explain why glyproline sequences have been used in peptide-stabilization research.

PGP Is Still Degradable

Research on PGP proteolysis has identified Gly-Pro as a degradation product.

Thus, even the stabilizing tripeptide is not chemically permanent.

A Stabilizing Fragment Can Have Its Own Metabolites

The complete degradation pathway can therefore involve:

• intact Semax
• partially shortened Semax peptides
• PGP
• smaller glyproline fragments

Each Species Is a Separate Potential Analyte

Detecting PGP after Semax exposure does not prove that intact Semax remains present.

Likewise, measuring an N-terminal Semax fragment does not directly quantify the parent peptide.

This Matters for Pharmacokinetic Interpretation

A useful analytical method should ideally determine whether the measured signal represents:

• intact MEHFPGP
• a peptide fragment
• an antibody-cross-reactive species

Biological Response Can Continue After Proteolysis

A parent peptide may initiate a signalling cascade before it is degraded.

The resulting:

• gene-expression changes
• protein phosphorylation
• secondary messenger changes

can persist after the parent peptide concentration has declined.

Therefore Response Duration Is Not Parent-Peptide Half-Life

If an experimental effect lasts several hours, that does not establish that intact Semax circulated or remained in tissue for the same duration.

The PGP Extension Can Influence Which Metabolites Form

Replacing the native ACTH(4-10) sequence R-W-G with P-G-P changes the available cleavage sites.

The resulting metabolite spectrum should therefore differ from that of native ACTH(4-10).

This Is Another Reason Semax Is Not ACTH(4-10)

Even if both contain seven residues, their:

• terminal chemistry
• protease susceptibility
• degradation products

are not expected to be identical.

The First Proline Removes an Arginine Position

ACTH(4-10) contains Arg at its fifth position.

Semax contains Pro.

This removes a basic side chain and replaces it with a conformationally restricted neutral residue.

The Glycine Replaces Tryptophan

Tryptophan is a large aromatic residue.

Glycine is the smallest amino acid.

This substitution dramatically changes steric and hydrophobic properties.

The Final Proline Replaces Glycine

The ACTH-derived comparator ends in Gly.

Semax ends in Pro.

This converts a highly flexible terminal residue into a restricted one.

The PGP Extension Also Disrupts the HFRW Motif

Classical melanocortin pharmacology involves the His-Phe-Arg-Trp sequence.

Semax instead contains:

His-Phe-Pro-Gly

across that region.

The PGP extension therefore contributes to Semax's separation from classical ACTH receptor pharmacology.

PGP Should Not Be Described as Biologically Inert

Glyproline peptides have their own experimental literature.

PGP has been examined independently in:

• proteolysis studies
• gene-expression experiments
• hemostatic models
• ischemia-associated animal research

Independent Activity Does Not Mean PGP Explains All Semax Findings

The relationship depends on the endpoint.

Some experiments have found partially overlapping responses between Semax and PGP.

Other experiments have found clear differences.

A Rat Ischemia Experiment Illustrates This Difference

One comparative study found that isolated PGP did not reproduce the neurological outcome reported for full-length Semax in that particular cerebral-ischemia model.

This indicates that the complete heptapeptide mattered for the endpoint tested.

Another Study Found Partly Overlapping Gene-Expression Effects

Research examining neurotrophin-related transcription after cerebral ischemia found that both Semax and PGP altered selected gene-expression measurements.

The profiles were not identical.

These Results Are Not Contradictory

Different experiments can measure:

• transcription
• neurological score
• survival
• protein expression

PGP can influence one molecular endpoint without reproducing the full phenotype associated with Semax in another experiment.

PGP and Semax Should Therefore Be Separate Comparator Groups

A well-controlled structure-function experiment can compare:

• vehicle
• PGP
• ACTH(4-7)
• Semax

to determine which structural component is associated with an observed response.

Molar Comparison Is More Informative Than Equal Mass Alone

PGP and Semax have different molecular masses.

Equal mass does not represent equal numbers of molecules.

Study design should specify how comparator concentrations were selected.

PGP Is Part of Semax but Is Not Synonymous With Semax

This distinction can be summarized precisely:

Every Semax molecule contains PGP, but PGP alone is not Semax.

The Same Applies to ACTH(4-7)

Semax contains MEHF, but MEHF alone is a different tetrapeptide.

The final heptapeptide should therefore be treated as its own experimental entity.

PGP Can Influence Physical Properties

Sequence extension changes:

• molecular size
• hydrogen-bonding possibilities
• hydrophobic surface
• terminal charge distribution

These changes can affect chromatographic and analytical behavior.

Chromatographic Retention May Differ From ACTH(4-7)

A longer peptide with two additional prolines and one glycine need not interact with a chromatographic stationary phase like the four-residue parent fragment.

Mass Spectrometry Can Distinguish the Structures

Semax, ACTH(4-7), and PGP have different:

• precursor masses
• fragment-ion patterns
• sequence-specific transitions

A Biological Assay Cannot Replace Analytical Identification

If a sample causes a response previously associated with Semax, that response does not prove the sample contains intact MEHFPGP.

Stability Claims Need a Defined Matrix

A peptide can have different degradation rates in:

• buffer
• nasal secretions
• blood
• brain-derived membrane preparations

There is no meaningful universal stability value independent of the experimental system.

Temperature Also Matters

Proteolytic and chemical degradation rates can depend on temperature.

A stability experiment performed under refrigerated storage conditions answers a different question from enzymatic degradation at physiological temperature.

Formulation pH Can Alter Chemical Stability

Peptide bonds and side chains may be affected by:

• acidic conditions
• alkaline conditions
• oxidizing environments

PGP-associated enzymatic resistance does not guarantee stability under every formulation condition.

Stabilization Does Not Establish Better Clinical Performance

A peptide that is degraded more slowly in an enzyme assay is not automatically:

• more effective
• safer
• more beneficial
• better absorbed

Those are separate experimental questions.

Longer Persistence Can Change Both Desired and Undesired Exposure

Pharmacokinetic persistence is a property, not inherently a benefit.

Interpretation requires knowing what biological interactions occur during that exposure.

PGP Does Not Establish Brain Delivery

Greater resistance to proteolysis does not prove that intact Semax reaches a particular brain compartment.

Distribution needs direct investigation.

Likewise, Intranasal Administration Does Not Prove Intact Central Exposure

Researchers must distinguish:

• nasal deposition
• absorption
• systemic exposure
• brain-associated radioactivity or peptide signal
• intact parent-peptide identification

Metabolite Detection Can Complicate Radiolabel Experiments

If a radiolabel remains attached to a fragment after peptide cleavage, detected radioactivity does not necessarily represent intact Semax.

Chemical separation can be needed to identify the molecular species carrying the label.

Why the PGP Extension Matters Beyond Stability

The extension simultaneously changes:

• sequence
• conformation
• charge relative to ACTH(4-10)
• proteolysis
• metabolite formation
• classical melanocortin motif integrity

This Makes PGP Part of Semax Identity

Removing PGP does not merely make Semax shorter.

It produces another peptide with a different chemical identity.

The Design Also Helps Explain Why Semax Is Not ACTH

Once three non-ACTH residues are appended immediately after ACTH(4-7), the resulting peptide differs even more strongly from full 39-residue ACTH.

The implications of that distinction are examined in Semax vs ACTH: Why the Peptide Should Not Be Treated as ACTH.

Reading a Direct Proteolysis Study

The PubMed-indexed paper Proteolysis of Simple Glyprolines by Leucine Aminopeptidase and Enzymes From Nasal Slime, Brain Membranes, and Rat Blood compares PGP-containing peptides with Semax and reports differences in their resistance to enzymatic degradation and in the peptide fragments formed during proteolysis.

The study provides direct evidence about glyproline stability and Semax degradation. It does not establish that the PGP extension makes Semax clinically effective, safe, superior, or appropriate for personal use.

Final Perspective

The Pro-Gly-Pro extension matters in Semax design because it converts the short ACTH(4-7) tetrapeptide into a chemically distinct seven-residue molecule.

PGP changes the terminal sequence, local conformation, protease-recognition environment, metabolite profile, and relationship to the classical ACTH(4-10) melanocortin sequence. Experimental research also shows that PGP can have its own molecular effects without reproducing every response of full-length Semax.

Research interpretation should therefore treat PGP as both a stabilizing design element and a biologically investigable structural region while keeping intact Semax, isolated PGP, ACTH(4-7), and degradation products as separate molecular entities.